A composition, products containing it and methods for its preparation and use thereof

Abstract

The present application relates to the technical field of medicine and daily chemical products, and discloses a composition, a product containing the same, a preparation method of the composition, and application of the composition.The composition comprises 0.8-1.2 parts of zinc pyrithione, 0.5-0.8 parts of salicylic acid, 0.1-0.2 parts of farnesol, 0.2-0.4 parts of gentiana scabra extract, 0.3-0.5 parts of portulaca oleracea extract, 0.5-1.0 parts of camellia sinensis seed cake extract, 0.1-0.3 parts of caffeine, and 0.3-0.5 parts of rosemary extract, in terms of mass fraction.The composition realizes improvement in aspects of skin lesion area, water content in the scalp stratum corneum, trans-epidermal water loss, oil secretion, high-temperature stability, centrifugal stability, freeze-thaw cycle stability, dandruff removal, anti-inflammatory effect, hair fixing, and / or anti-itching effect.

Description

Technical Field

[0001] This invention relates to the fields of pharmaceuticals and daily chemical products, and more specifically to a composition, a product containing the composition, a method for preparing the composition, and its uses. Background Technology

[0002] Seborrheic dermatitis is a chronic, inflammatory skin disease that commonly occurs on the scalp, face, chest, and back—areas with excessive sebum production. Perifolliculitis-related papules are the initial lesions, which gradually enlarge and merge as the condition progresses, forming dark red or yellowish-red patches of varying sizes with clear borders, covered with greasy scales or crusts. Exudation, crusting, and erosion may occur, and it can present with eczema-like symptoms, accompanied by itching. The disease has a chronic course and can recur. Seborrheic dermatitis is one of the most common dermatological diseases, with an incidence rate of approximately 2%-5% in adults. With improved living standards and changes in dietary habits, the incidence rate is increasing year by year. Scalp seborrheic dermatitis, accompanied by itching and dandruff, seriously affects the physical and mental health of patients, and people are increasingly aware of the importance of this disease. However, existing technologies and products need improvement in many aspects, including lesion area, scalp stratum corneum water content, transepidermal water loss, sebum secretion, high-temperature stability, centrifugal stability, freeze-thaw cycle stability, dandruff removal, anti-inflammation, hair strengthening, and antipruritic effects. Summary of the Invention

[0003] This invention provides a composition, a product containing the same, a method for preparing the same, and its uses, to address various issues that need improvement, such as lesion area, scalp stratum corneum moisture content, transepidermal water loss, sebum secretion, high temperature stability, centrifugal stability, freeze-thaw cycle stability, dandruff removal, anti-inflammation, hair strengthening, and itch relief.

[0004] In a first aspect, the present invention provides a composition, characterized in that, by weight, it comprises 0.8-1.2 parts of zinc pyrithione, 0.5-0.8 parts of salicylic acid, 0.1-0.2 parts of bisabolol, 0.2-0.4 parts of gentian extract, 0.3-0.5 parts of purslane extract, 0.5-1.0 parts of camellia seed cake extract, 0.1-0.3 parts of caffeine, and 0.3-0.5 parts of rosemary extract.

[0005] In one alternative implementation, at least one of the following is satisfied: (a) The composition comprises, by weight, 1.0 parts zinc pyrithione, 0.6 parts salicylic acid, 0.15 parts bisabolol, 0.3 parts gentian extract, 0.4 parts purslane extract, 0.75 parts camellia seed cake extract, 0.2 parts caffeine, and 0.4 parts rosemary extract; (b) The composition does not include selenium disulfide.

[0006] In one alternative implementation, at least one of the following is satisfied: (a) The gentian extract includes gentiopicrin; (b) Purslane extract includes quercetin; (c) Camellia seed cake extract includes tea saponins; (d) Rosemary extract includes rosmarinic acid; (e) The salicylic acid is supramolecular salicylic acid, wherein the supramolecular salicylic acid contains 0.5-0.8 parts of salicylic acid.

[0007] In one alternative implementation, at least one of the following is satisfied: (a) The salicylic acid is supramolecular salicylic acid, wherein the supramolecular salicylic acid contains 0.6 parts of salicylic acid; (b) The composition further comprises, by weight, 12.0-14.0 parts sodium lauryl ether sulfate, 4.0-5.0 parts cocamidopropyl betaine, and 2.0-3.0 parts cocamidopropylamine oxide.

[0008] In an optional embodiment, the aforementioned composition further comprises the following substances in parts by weight: 0.8-1.0 parts of phenoxyethanol, 0.3-0.5 parts of ethylhexylglycerin, 0.5-1.0 parts of panthenol, 0.1-0.2 parts of menthol, and / or 0.15-0.25 parts of hydrogenated castor oil.

[0009] In an optional embodiment, the aforementioned composition further comprises the following substances in parts by weight: 0.6 parts of phenoxyethanol, 0.1 parts of ethylhexylglycerin, 0.5 parts of panthenol, 0.15 parts of menthol, and / or 0.2 parts of hydrogenated castor oil.

[0010] Secondly, the present invention also provides a method for preparing the aforementioned composition, comprising: A first mixture was prepared by mixing water with glycerol, panthenol, and sodium gluconate. Sodium lauryl ether sulfate, cocamidopropyl betaine, and cocamidopropylamine oxide were added to the first mixture and mixed to prepare the second mixture. Zinc pyrithione was mixed with hydrogenated castor oil and propylene glycol to prepare a third mixture; Add stearamide-propyl dimethylamine and polyquaternium-7 to the first mixture, mix, and prepare the fourth mixture; Add the third mixture and supramolecular salicylic acid to the fourth mixture to obtain the fifth mixture; Add bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract to the fifth mixture to obtain the sixth mixture.

[0011] In one alternative implementation, at least one of the following is satisfied: (a) Mix at 75±2℃ to prepare the first mixture; (b) Mix at 30 rpm to prepare the first mixture; (c) Mix for 15 min to prepare the first mixture; (d) Mix at 75±2℃ to prepare a second mixture; (e) Mix at 50 rpm to prepare a second mixture; (f) Mix for 20 min to prepare a second mixture; (g) Hydrogenated castor oil is PEG-40 hydrogenated castor oil; (h) The hydrogenated castor oil has a mass percentage concentration of 0.2%; (i) The mass percentage concentration of propylene glycol is 1%; (j) Mix at 5000 rpm to prepare a third mixture; (k) Mix for 10 min to prepare the third mixture; (l) Stearamide-propyl dimethylamine and polyquaternium-7 were added to the first mixture at 70±2℃ to prepare the fourth mixture; (m) Mix at 5000 rpm to prepare a fourth mixture; (n) Mix for 15 min to prepare the fourth mixture; (o) Cool the fourth mixture to 60°C, add the third mixture and supramolecular salicylic acid to the fourth mixture to obtain the fifth mixture; (p) Cool the fifth mixture to 45°C, and add bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract to the fifth mixture to obtain the sixth mixture; (q) The preparation method of supramolecular salicylic acid includes: mixing salicylic acid with cyclodextrin; (r) In the preparation method of supramolecular salicylic acid, salicylic acid is mixed with β-cyclodextrin; (s) In the preparation method of supramolecular salicylic acid, salicylic acid and cyclodextrin are mixed in a mass ratio of 1:3; (t) In the preparation method of supramolecular salicylic acid, the mixture is mixed at 50°C; (u) In the preparation method of supramolecular salicylic acid, the mixture is mixed for 2 hours.

[0012] In one alternative implementation, at least one of the following is satisfied: (a) The mass ratio of water to glycerol, panthenol, and sodium gluconate is (68–72):(1.8–2.2):(0.4–0.6):(0.2–0.4). (b) The mass ratio of the first mixture to sodium lauryl ether sulfate, cocamidopropyl betaine, and cocamidopropylamine oxide is (71.0–74.6):(2.3–2.7):(1.8–2.2):(0.8–1.2). (c) The mass ratio of zinc pyrithione to hydrogenated castor oil and propylene glycol is (0.9–1.1):(0.15–0.25):(0.9–1.1); (d) The mass ratio of the first mixture to stearamide propyl dimethylamine and polyquaternium-7 is (71.0–74.6):(1.3–1.7):(0.8–1.2). (e) The mass ratio of the fourth mixture to the third mixture and supramolecular salicylic acid is (73.8–76.8):(9.0–11.0):(11.0–13.0); (f) The mass ratio of the fifth mixture to bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract is (96.0–98.6):(0.13–0.17):(0.18–0.22):(0.18–0.22):(0.35–0.45):(0.18–0.22):(0.18–0.22). (g) Adjust the pH of the sixth mixture to 5.5–6.0; (h) Adjust the viscosity of the sixth mixture to 8000-12000 cps.

[0013] In one alternative implementation, at least one of the following is satisfied: (a) The mass ratio of water to glycerol, panthenol, and sodium gluconate is 70:2:0.5:0.3; (b) The mass ratio of the first mixture to sodium lauryl ether sulfate, cocamidopropyl betaine, and cocamidopropylamine oxide is 72.8:2.5:2.0:1.0; (c) The mass ratio of zinc pyrithione to hydrogenated castor oil and propylene glycol is 1:0.2:1; (d) The mass ratio of the first mixture to stearamide propyl dimethylamine and polyquaternium-7 is 72.8:1.5:1.0; (e) The mass ratio of the fourth mixture to the third mixture and supramolecular salicylic acid is 75.3:10:12; (f) The mass ratio of the fifth mixture to bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract was 97.3:0.15:0.2:0.2:0.4:0.2:0.2; (g) Adjust the pH of the sixth mixture prepared by the aforementioned method of composition to 5.5-6.0; (h) The viscosity of the sixth mixture prepared by the aforementioned method of preparing the composition is 8000-12000 cps.

[0014] In an optional embodiment, the preparation method further includes: before adjusting the pH of the sixth mixture, adding phenoxyethanol, ethylhexylglycerin, menthol, and camphor to the sixth mixture, optionally adding the following substances in parts by weight: 0.6-0.8 parts phenoxyethanol, 0.1-0.3 parts ethylhexylglycerin, 0.15-0.25 parts menthol, and 0.05-0.15 parts camphor to the sixth mixture.

[0015] In an optional embodiment, after adding phenoxyethanol, ethylhexylglycerin, menthol, and camphor to the sixth mixture, the mixture is stirred at 15–25 rpm for 10–20 min, or optionally at 20 rpm for 15 min.

[0016] In an optional embodiment, the preparation method uses the following mass parts of phenoxyethanol, ethylhexylglycerin, panthenol, menthol, and hydrogenated castor oil: 0.8-1.0 parts of phenoxyethanol, 0.3-0.5 parts of ethylhexylglycerin, 0.5-1.0 parts of panthenol, 0.1-0.2 parts of menthol, and / or 0.15-0.25 parts of hydrogenated castor oil.

[0017] In an optional embodiment, the preparation method uses the following mass parts of phenoxyethanol, ethylhexylglycerin, panthenol, menthol, and hydrogenated castor oil: 0.6 parts phenoxyethanol, 0.1 parts ethylhexylglycerin, 0.5 parts panthenol, 0.15 parts menthol, and / or 0.2 parts hydrogenated castor oil.

[0018] Thirdly, the present invention also provides the use of the aforementioned composition or the composition prepared by the aforementioned method in the preparation of products, wherein the products are selected from pharmaceuticals and daily chemical products.

[0019] In one alternative implementation, at least one of the following is satisfied: (a) The product is shampoo; (b) The product improves the area of ​​skin lesions, scalp stratum corneum moisture content, transepidermal water loss, sebum secretion and / or the quality of life index of dermatitis; (c) The product has high temperature stability, centrifugal stability, and freeze-thaw cycle stability; (d) The product is used for dandruff removal, anti-inflammation, hair strengthening and / or itch relief; (e) The product is a cosmetic; (f) The pH of the product is 5.5-6.0; (g) The product is a shampoo with a viscosity of 8000-12000 cps; (h) The product promotes the proliferation of dermal papilla cells; (i) The product inhibits Malassezia; (j) The product inhibits the expression of at least one of the inflammatory factors IL-6, IL-8 and TNF-α.

[0020] In this invention, "high temperature" means 40℃-50℃.

[0021] The technical solution of this invention has the following advantages: 1. The composition provided by the present invention, through specific amounts of components, achieves improvements in multiple aspects, including lesion area, scalp stratum corneum water content, transepidermal water loss, sebum secretion, high temperature stability, centrifugal stability, freeze-thaw cycle stability, dandruff removal, anti-inflammation, hair strengthening, antipruritic effect, ASFS, NRS, DLQI, dermal papilla cell proliferation, inhibition of Malassezia, and inhibition of the expression of inflammatory factors IL-6, IL-8 and / or TNF-α.

[0022] 2. The shampoo provided by the present invention, by employing the specific composition of the present invention, achieves improvements in multiple aspects such as lesion area, scalp stratum corneum moisture content, transepidermal water loss, sebum secretion, high temperature stability, centrifugal stability, freeze-thaw cycle stability, dandruff removal, anti-inflammation, hair strengthening, anti-itch, ASFS, NRS and / or DLQI. Attached Figure Description

[0023] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0024] Figure 1 This is the effect diagram corresponding to Table 4. Figure 1 The left side of the image corresponds to the control group, and the right side corresponds to the observation group. Detailed Implementation

[0025] The following embodiments are provided to better understand the present invention, but the following embodiments do not constitute a limitation on the content and scope of protection of the present invention. Any product that is the same as or similar to the present invention, derived by any person under the guidance of the present invention or by combining the features of the present invention with other prior art, falls within the scope of protection of the present invention.

[0026] Unless otherwise specified, all experimental steps or conditions in the examples were performed according to conventional experimental procedures and conditions in the art. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0027] The shampoo of the present invention was prepared using the ingredient formula shown in Table 1: Table 1 Shampoo Ingredients and Formula

[0028] Example 1 1. Raw material pretreatment (1) Aqueous phase preparation: Add 70 g of deionized water to the reaction vessel and heat to 75±2℃. Add 2.0 g of glycerol, 0.5 g of panthenol and 0.3 g of sodium gluconate. Stir at 30 rpm for 15 min to obtain 72.8 g of the first mixture.

[0029] (2) Preparation of the second mixture Keep the temperature of the first mixture at 75±2℃, add 13.0 parts by weight of sodium lauryl ether sulfate, 4.5 parts by weight of cocamidopropyl betaine, and 2.5 parts by weight of cocamidopropylamine oxide to the first mixture, and stir at 50 rpm for 20 min to obtain the second mixture.

[0030] (3) Preparation of the third mixture 1.0 g of zinc pyrithione, 0.2 g of PEG-40 hydrogenated castor oil and 1.0 g of propylene glycol were mixed and stirred at 5000 rpm for 10 min to obtain the third mixture.

[0031] (4) Preparation of supramolecular salicylic acid 0.6 g of salicylic acid and 1.8 g of β-cyclodextrin were mixed in a mass ratio of 1:3 and stirred at 50 °C for 2 hours to prepare supramolecular salicylic acid.

[0032] 2. Mixing and emulsification in the main reactor (1) Basic matrix synthesis (preparation of the fourth mixture) The first mixture (72.8 g) was added to the main reactor and the temperature was controlled at 70±2℃. 1.5 g stearamide propyl dimethylamine and 1.0 g polyquaternium salt-7 were added to the first mixture and mixed at 5000 rpm for 15 min to obtain the fourth mixture.

[0033] (2) Preparation of the fifth mixture The fourth mixture was cooled to 60°C, and 10 g of the third mixture and 12 g of supramolecular salicylic acid were added to the fourth mixture. The mixture was stirred at 30 rpm for 10 min to obtain the fifth mixture.

[0034] (3) Preparation of the sixth mixture The fifth mixture was cooled to 45°C, and 0.15 g bisabolol, 0.2 g gentian extract, 0.2 g purslane extract, 0.4 g camellia seed cake extract, 0.2 g caffeine, and 0.2 g rosemary extract were added to the fifth mixture. The mixture was stirred until homogeneous to obtain the sixth mixture.

[0035] 3. Post-processing and filling pH and viscosity adjustment Adjust the pH of the sixth mixture to 5.5–6.0 with a 10% citric acid solution; add an appropriate amount of sodium chloride to adjust the viscosity to 8000–12000 cps (Brookfield RV, Spindle 6, 20 rpm) to obtain the shampoo.

[0036] Example 2 The only difference from Example 1 is that the following is included before "pH and viscosity adjustment": Add 0.6 g phenoxyethanol, 0.1 g ethylhexylglycerin, 0.15 g menthol, and 0.05 g camphor to the sixth mixture, and stir at 20 rpm for 15 min.

[0037] Experimental Example 1 The shampoo prepared in Example 1 was subjected to the following tests: I. Stability Testing: 1) High-temperature stability: Test method: Accelerated stability test 1. Take the sample to be tested and seal it in a clean container.

[0038] 2. Place in a 40℃ constant temperature oven / stability test chamber for 90 days.

[0039] 3. Observe at 0, 30, 60, and 90 days respectively: Appearance: Whether it is layered, cloudy, discolored, or has an unusual odor. Whether there is sedimentation, flocculation, oil separation, or water separation.

[0040] The results showed that at 40℃ for 90 days, there was no stratification, discoloration, or precipitation.

[0041] (ii) Centrifugal stability: Detection method: 1. Place the sample in a centrifuge tube and seal it.

[0042] 2. Use a benchtop centrifuge at 3000 r / min for 30 min.

[0043] 3. Remove and observe: The presence or absence of precipitation, stratification, crystallization, flocculation, or floating oil was observed. Results showed no precipitation.

[0044] (iii) Freeze-thaw cycle: Detection method: 1. Seal the sample.

[0045] 2. Loop condition: Freeze at -10℃ for 12-18 hours, then remove and place at 25℃ room temperature for 12-18 hours. This is one cycle.

[0046] 3. Repeat the cycle 3 times.

[0047] 4. Observe after returning to room temperature: Appearance, clarity, presence of emulsion breakage, layering, clumping, and discoloration. Cycle 3 times from -10℃ to 25℃, and the properties return to normal after returning to room temperature.

[0048] II. Heavy Metal Detection: 1) Detection of lead Methods: Atomic absorption spectrophotometry (AAS) or ICP-MS Commonly used standards and bases: GB 5009.12-2017 National Food Safety Standard: Determination of Lead in Food Or cosmetics: GB 7917.2-2019 Cosmetic Safety Standard - Lead Brief steps: Sample wet digestion / microwave digestion (nitric acid + hydrogen peroxide) After adjusting the volume, the samples were determined by flame / graphite furnace atomic absorption or ICP-MS.

[0049] 2) Detection of arsenic Method: Atomic fluorescence spectrometry (AFS) preferred in accordance with: GB 5009.11-2014 Determination of total arsenic and inorganic arsenic in food Cosmetics: GB 7917.2-2019 Arsenic step: Thiourea-ascorbic acid pre-reduction after digestion Total arsenic was measured using an atomic fluorescence spectrophotometer.

[0050] 3) Detection of mercury Method: Atomic fluorescence spectrometry (AFS) in accordance with: GB 5009.17-2021 Determination of total mercury and organic mercury in food Cosmetics: GB 7917.2-2019 Mercury step: Total mercury determination using cold atomic absorption / atomic fluorescence.

[0051] The results showed that lead ≤10ppm, arsenic ≤2ppm, and mercury ≤1ppm.

[0052] III. Efficacy Verification Requirements Dandruff reduction test: In accordance with the "Evaluation Standards for Cosmetic Efficacy Claims", a 28-day human clinical trial was conducted, and the dandruff reduction rate was ≥30%.

[0053] Anti-inflammatory data: In vitro cell experiments demonstrated an inhibition rate of ≥50% of TNF-α release.

[0054] Hair strengthening effect: Provides experimental report on the synergistic effect of caffeine and camellia extract in promoting hair follicle cell proliferation (MTT method, proliferation rate ≥20%).

[0055] Experiment Example 2 This study investigated the effects of the shampoo prepared in Example 1 and selenium sulfide on patients with seborrheic dermatitis admitted to our dermatology department. Specifically, a control group treated with selenium sulfide alone and an observation group treated with the shampoo prepared in Example 1 were compared. The control group consisted of 41 patients, and the observation group consisted of 43 patients. There were no statistically significant differences in general characteristics between the two groups (p > 0.05), as shown in Table 2.

[0056] Table 2 Comparison of basic information of patients with seborrheic dermatitis of the scalp between the two groups

[0057] Specific application method: The control group received selenium sulfide three times a week. 5-10 ml of selenium sulfide shampoo (produced by Jiangsu Disano Pharmaceutical Co., Ltd., National Drug Approval Number H1080003, specification: 2.5%×100g) was applied to wet hair and scalp, gently rubbed until foamy, and the scalp was massaged for 15 minutes. The solution was left on the scalp for 5 minutes before rinsing thoroughly. Application was continued for 3 months. The observation group used the shampoo prepared in Example 1, with the same dosage and application method as the selenium sulfide shampoo.

[0058] Effectiveness evaluation criteria Efficacy assessment criteria: Based on SSRI, it is divided into four levels: Excellent (efficacy index ≥ 90%), Significantly Effective (efficacy index 61%–89%), Effective (efficacy index 21%–60%), and Ineffective (efficacy index ≤ 20%). Overall effective rate = (Number of excellent cases + Number of significantly effective cases) / Total number of cases × 100%.

[0059] Observation indicators Area of ​​skin lesions The area of ​​skin lesions was recorded before application, 1 week after application, 1 month after application, and 3 months after application.

[0060] scalp condition The scalp condition of the two groups of patients was compared before and 3 months after application. The scalp stratum corneum moisture content, transepidermal water loss (TEWL), and sebum secretion were measured using CM825 and Meibometer560 manufactured by ck GmbH, Germany.

[0061] Other ratings Assess the following scores before application and 3 months after application. The Scalp Scale Adhesion Scale (ASFS) divides the scalp into 8 zones, with each zone's dandruff scored on a scale of 0-10, for a total of 80 points. A higher total score indicates more severe dandruff. Scalp itching is assessed using a Numerical Rating Scale (NRS), with a maximum score of 10 points; the score is directly proportional to the degree of itching. The Dermatology Quality of Life Index (DLQI) has a total score of 30 points; a higher score indicates a poorer quality of life related to dermatology.

[0062] The results are shown in Table 3-7 below. Table 3 Comparison of total effective rate between the two groups of patients with seborrheic dermatitis of the scalp [n(%)]

[0063] Note: This indicates that compared with the control group, p < 0.05.

[0064] Table 4 Comparison of lesion area before and after application in two groups of patients with seborrheic dermatitis of the scalp (x±s, cm2)

[0065] Note: ＃ Indicates a comparison with the group before application. p＜ 0.05; This indicates a comparison with the control group after administration. p＜ 0.05.

[0066] Table 5 Comparison of scalp condition before and after application in two groups of patients with seborrheic dermatitis of the scalp (x±s)

[0067] Note: ＃This indicates a comparison with the group before application. p＜ 0.05; This indicates a comparison with the control group at the same time point. p＜ 0.05.

[0068] Table 6. Comparison of inflammation levels before and after application in two groups of patients with scalp seborrheic dermatitis (x±s)

[0069] Note: # indicates p < 0.05 compared to before administration in this group; This indicates that compared with the control group, p < 0.05.

[0070] Table 7 Comparison of ASFS, NRS and DLQI scores before and after treatment in two groups of patients with seborrheic dermatitis of the scalp (x±s, points)

[0071] Note: ＃ Indicates a comparison with the group before application. p＜ 0.05; This indicates a comparison with the control group after administration. p＜ 0.05.

[0072] Results Analysis Comparison of clinical effects between the two groups The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant. p＜ 0.05), see Table 2.

[0073] Comparison of skin lesion area before and after treatment in two groups of patients Before application, there was no statistically significant difference in the area of ​​skin lesions between the two groups. p> The skin lesion area in the observation group was significantly smaller than that in the control group at 1 week, 1 month, and 3 months after application (0.05%). p＜ 0.05), see Table 4. Figure 1 .

[0074] Comparison of scalp condition before and after application in two groups of patients There was no statistically significant difference in scalp condition between the two groups of patients before application. p> 0.05), after 3 months of treatment, the stratum corneum moisture content in the observation group was higher than that in the control group, while the sebum secretion and TEWL were lower, and the differences were statistically significant. p＜ 0.05), as shown in Table 5.

[0075] Comparison of inflammatory factor levels before and after administration in the two groups Before application, there was no statistically significant difference in the levels of inflammatory factors between the two groups. p>The level of inflammatory factors in the observation group was lower than that in the control group after treatment (0.05), and the difference was statistically significant. p＜ 0.05), see Table 6.

[0076] Comparison of ASFS, NRS evaluation and DLQI before and after application in two groups There were no statistically significant differences in ASFS, NRS assessment, and DLQI between the two groups before application. p> The ASFS, NRS, and DLQI scores of the observation group were all lower than those of the control group after treatment (0.05), and the differences were statistically significant. p＜ 0.05), as shown in Table 7.

[0077] Experiment Example 3: Hair papilla cell proliferation experiment 1. Preparation of working solutions (suitable for 10 systems): Prepare working solutions for each single compound and the combined working solutions according to the 10 corresponding concentrations shown below. Use sterile PBS buffer (pH 7.4) as the solvent, stir magnetically at room temperature for 30 min until completely dissolved, and prepare the stock solution. Then, sterilely filter through a 0.22 μm polyethersulfone filter membrane to remove microorganisms and insoluble impurities. Aliquot into sterile cryovials, label each tube with the group, concentration and preparation time, and store at 4°C for later use. Prepare and use immediately to avoid repeated freeze-thaw cycles that may reduce compound activity or cause concentration deviations.

[0078] 10 corresponding concentrations: The blank control group (Group 1) contained only cell culture medium, without the addition of any compounds; The compound concentrations were the optimal safe concentrations, specifically: Group 2 (zinc pyrithione 0.075 mg / mL), Group 3 (supramolecular salicylic acid 0.03 mg / mL), Group 4 (bisabolol 0.05 mg / mL), Group 5 (gentiopicroside 0.05 mg / mL), Group 6 (quercetin 0.04 mg / mL), Group 7 (tea saponin 0.065 mg / mL), Group 8 (caffeine 0.025 mg / mL), and Group 9 (rosmarinic acid 0.03 mg / mL). In Group 10 (composition, concentration ≈ 0.0468 mg / mL), the composition contains the following components by mass: 1.0 parts zinc pyrithione, 0.65 parts salicylic acid (specifically, 12 parts supramolecular salicylic acid containing 0.65 parts salicylic acid), 0.15 parts bisabolol, 0.3 parts gentiopicrin, 0.4 parts quercetin, 0.75 parts tea saponin, 0.2 parts caffeine, and 0.4 parts rosmarinic acid. The total mass is 1.0 + 0.65 + 0.15 + 0.3 + 0.4 + 0.75 + 0.2 + 0.4 = 4.25 parts.

[0079] 2. Cell Seeding: Dermal papilla cells in the logarithmic growth phase were digested with 0.25% trypsin, centrifuged (1000 rpm, 5 min), and the supernatant was discarded. The cells were resuspended in complete culture medium and the cell density was adjusted to 5 × 10³ cells / well. Ten cell culture systems were arranged in 96-well plates, and 100 μL of cell suspension was added to each well. 100 μL of sterile PBS buffer was added to the edge wells to eliminate edge effects caused by culture medium evaporation and to ensure that the experimental conditions in the edge wells were consistent with those in the center wells.

[0080] 3. Cell adherence culture: After inoculation, the 96-well plates were placed in a constant temperature incubator at 37℃ and 5% CO2 and cultured statically for 24 hours. The cell status was observed daily. When the cell adhesion and confluence rate reached 70%~80%, the morphology was uniform and there was no contamination, drug treatment was performed.

[0081] 4. Grouped drug administration: Discard the old culture medium from each well of the 96-well plate, and precisely add the corresponding working solution according to the group: Group 1 (blank control group) adds 100 μL of complete culture medium; Groups 2-9 (single compound groups) add 100 μL of the corresponding concentration of single compound working solution; Group 10 (combination group) adds 100 μL of the combination working solution. After drug administration, gently shake the culture plate (amplitude ≤10°) to ensure the working solution evenly covers the cell surface and prevents cell detachment.

[0082] 5. Time-sequential culture: After drug administration, the 96-well plate was returned to a 37°C, 5% CO2 incubator and cultured for 48 hours.

[0083] 6. CCK-8 reagent addition and incubation: 2 hours in advance, take out the corresponding culture plate, add 10 μL of CCK-8 reagent to each well, gently pipette to mix (avoid generating air bubbles to avoid interfering with absorbance detection), and place in an incubator to incubate in the dark for 2 hours to ensure that the reagent reacts fully with the cells and generates a stable chromogenic product.

[0084] 7. Absorbance detection: After incubation, remove the culture plate and measure the absorbance (OD value) of each well at a wavelength of 450 nm using a microplate reader. Measure each well three times and take the average value as the final OD value of that well. At the same time, set up blank wells (containing only 100 μL of complete culture medium + 10 μL of CCK-8 reagent) and measure their OD values ​​as background values ​​for subsequent data correction.

[0085] 8. Experimental Reproducibility and Quality Control: Each group was configured with 6 replicates, and 3 independent experiments were conducted in parallel. Freshly prepared working solution and freshly seeded cells were used in each experiment to avoid the impact of single-experiment errors on the reliability of the results. The incubator temperature, CO2 concentration, and reagent usage were recorded during the experiment as a basis for experimental quality control.

[0086] 9. Cell status observation: 48 hours after drug administration, the morphology, density and apoptosis of each component cells were observed simultaneously using an inverted microscope. Any abnormal phenomena such as cell shrinkage, fragmentation, and shedding were recorded. The effect of the compound on the cells was determined by combining the OD value data.

[0087] 10. Experimental Conclusion: After the test is completed, discard the liquid in the culture plate, wash twice with sterile PBS buffer, dispose of the waste culture plate and reagents in accordance with biosafety procedures, organize the experimental data and enter it into the database for subsequent statistical analysis.

[0088] 11. Formula for calculating cell proliferation rate: Cell proliferation rate = (OD value of experimental group - OD value of blank control group) / OD value of blank control group × 100%; Judgment criteria: Proliferation rate > 0%, indicating that the compound has the activity of promoting the proliferation of dermal papilla cells. The higher the proliferation rate, the stronger the activity; The proliferation rate of the combined group was significantly higher than that of each single compound group (P<0.05), indicating that there is a synergistic effect among the components.

[0089] 12. Experimental Results The results showed that there was no statistically significant difference between the zinc pyrithione group, salicylic acid group, bisabolol group, and gentiopicroside group and the control group (p>0.05), with relative activity (proliferation rate) between 99.3% and 99.8%. Rosmarinic acid had a relative activity of 111.9%, indicating a weak promoting effect; quercetin had a relative activity of 113.6%, indicating a moderate promoting effect; tea saponin had a relative activity of 115.5%, indicating a strong promoting effect; caffeine had a relative activity of 117.0%, indicating a strong promoting effect; and the combination had a relative activity of 130.2%, indicating the strongest promoting effect, significantly better than the single component.

[0090] Experiment Example 4: Experiment on Inhibiting Malassezia 1. Experimental Groups: The core groupings are completely consistent with the dermal papilla cell proliferation experiment, and the dosages are uniformly based on the optimal safe concentration for HaCat cell screening. Positive and negative controls are added to ensure experimental validity, and the group numbering corresponds to the previous text to ensure system consistency. Blank control group (Group 1, core system): containing only Sabouraud liquid culture medium, without compounds and Malassezia, serving as a sterile control and OD value background correction benchmark.

[0091] Negative control group (newly added quality control): Sandberg liquid medium + Malassezia bacterial suspension, free of compounds, used as the normal growth benchmark for Malassezia and for calculating the inhibition rate.

[0092] Single compound groups (groups 2-9, core system, 8 groups in total): Sandburg liquid medium + Malassezia inoculum + corresponding single compound, with the compound concentration at the optimal safe concentration, specifically: Group 2 (zinc pyrithione 0.075 mg / mL), Group 3 (supramolecular salicylic acid 0.03 mg / mL), Group 4 (bisabolol 0.05 mg / mL), Group 5 (gentiopicroside 0.05 mg / mL), Group 6 (quercetin 0.04 mg / mL), Group 7 (tea saponin 0.065 mg / mL), Group 8 (caffeine 0.025 mg / mL), Group 9 (rosmarinic acid 0.03 mg / mL).

[0093] Composition Group (Group 10, Core System): Sandberg liquid medium + Malassezia bacterial suspension + composition working solution, composition concentration ≈ 0.0468 mg / mL, the mass ratio of the composition is: 1.0 part zinc pyrithione, 0.65 parts supramolecular salicylic acid, 0.15 parts bisabolol, 0.3 parts gentiopicrin, 0.4 parts quercetin, 0.75 parts tea saponin, 0.2 parts caffeine, 0.4 parts rosmarinic acid, total mass parts = 1.0 + 0.65 + 0.15 + 0.3 + 0.4 + 0.75 + 0.2 + 0.4 = 4.25 parts.

[0094] Positive control group (newly added quality control): Sabouraud liquid medium + Malassezia bacterial suspension + ketoconazole solution (0.05 mg / mL), as a positive control for antibacterial activity, to verify the effectiveness of the experimental system (ketoconazole is a commonly used antifungal drug with a clear antibacterial effect).

[0095] 2. Experimental Procedure: (1) Preparation and activation of Malassezia bacterial suspension: ① Take out the frozen Malassezia standard strain, pick up a small amount of bacterial suspension with a sterile inoculation loop, streak it onto an SDA medium plate, and incubate at 30℃ for 48h to complete the activation, ensuring the purity and activity of the strain; ② After activation, gently scrape the single colony on the plate with sterile physiological saline, collect it into a sterile centrifuge tube, shake to mix, and adjust the bacterial suspension concentration to 1×10⁻⁶ with physiological saline. 6 CFU / mL (calibrated using a hemocytometer), shake for 10 min to ensure uniform dispersion of the bacterial solution, then set aside.

[0096] (2) Preparation of compound working solutions: ① According to the concentration requirements of each group, use Saburg liquid medium as solvent to dissolve each single compound, the combination and ketoconazole separately, and stir magnetically at room temperature for 30 minutes until completely dissolved to avoid compound residue affecting the antibacterial effect; ② All working solutions are aseptically filtered through a 0.22μm polyethersulfone filter membrane (to remove contaminants and ensure experimental purity), dispensed into sterile centrifuge tubes, labeled with group, concentration and preparation time, and stored at 4℃ for later use. Prepare and use immediately, and do not repeatedly freeze and thaw.

[0097] (3) Plating and grouping of 96-well plates: ① Arrange the 96-well plates according to the grouping order, mark the groups, and add 100 μL of Saburg liquid medium to each well; ② Grouping and adding: Add 50 μL of the corresponding working solution to each core experimental group (groups 1, 2-9, and 10) and the positive control group, and add 50 μL of sterile PBS buffer to the blank control group and the negative control group. Gently shake the 96-well plate (horizontal shaking, amplitude ≤10°) to mix the liquid thoroughly; ③ Inoculation of bacterial suspension: Except for the blank control group, accurately add 50 μL of the prepared Malassezia bacterial suspension to each well of each other group, so that the final volume of each well is 200 μL and the final concentration of the bacterial suspension is uniformly 2.5 × 10⁻⁶. 5 CFU / mL; after inoculation, gently blow three times with a sterile pipette tip (avoid generating air bubbles) to ensure that the bacterial solution is in full contact with the working solution / culture medium.

[0098] (4) Constant temperature incubation: Place the inoculated 96-well plate in a 30℃ CO2-free constant temperature incubator and incubate for 48 hours. Do not shake during the incubation period to prevent Malassezia from precipitating and affecting the OD value measurement. Observe the liquid state in the wells daily and record any abnormalities such as contamination or bacterial film formation.

[0099] (5) OD 600 OD value determination: ① After 48 hours of incubation, remove the 96-well plate and gently shake for 1 minute (to evenly disperse the Malassezia bacteria precipitated at the bottom of the wells, ensuring accurate OD value measurement); ② Preheat the microplate reader for 30 minutes and calibrate the wavelength to 600 nm (OD). 600 ③ Set the measurement parameters (measure 3 times per well and take the average value); ③ Place the plate in a 96-well plate and measure the OD value of each well in the order of grouping. At the same time, record the OD values ​​of the blank control group, negative control group, and positive control group as the basis for subsequent data correction and experimental validity determination.

[0100] (6) Data correction and antibacterial rate calculation: ① Data correction: The corrected OD value of each group = the measured average OD value of the group - the average OD value of the blank control group (after deducting the background interference of the culture medium); ② Antibacterial rate calculation: The antibacterial rate of each group is calculated according to the formula "antibacterial rate (%) = (corrected OD value of negative control group - corrected OD value of experimental group) / corrected OD value of negative control group × 100%"; ③ Data processing: Record the antibacterial rate of each group in 3 independent experiments, calculate the mean and standard deviation (SD) of the antibacterial rate of each group, and use them for bar chart drawing and statistical analysis.

[0101] 3. Experimental Results (Inhibition Rate): No inhibition: Bisabolol (1.7%), quercetin (2.3%), and caffeine (-1.1%) showed no difference from the control group (p>0.05); Moderate inhibition: Rosmarinic acid (49.6%) and supramolecular salicylic acid (52.8%) (p<0.05); Strong inhibition: Gentianoside (73.0%), zinc pyrithione (79.3%), and tea saponin (85.7%) (p<0.05); The antibacterial rate of the combined group was 95.1%, significantly better than all single components (p<0.05), and comparable to ketoconazole (94.2%).

[0102] Experiment Example 5: An Experiment to Inhibit Inflammation This experiment established an inflammation model by inducing dermal papilla cells with lipopolysaccharide (LPS). The expression levels of inflammatory factors IL-6, IL-8, and TNF-α were detected by ELISA. The anti-inflammatory activities of each compound and combination were quantitatively evaluated to clarify the synergistic anti-inflammatory effect.

[0103] 1. Preparation of compound working solutions: According to the optimal safety concentration of each group (the grouping and related concentrations are the same as in Experiments 3 and 4), each single compound and the combination are dissolved separately in complete culture medium. The solution is magnetically stirred at room temperature for 30 min until completely dissolved. The solution is then aseptically filtered through a 0.22 μm polyethersulfone filter membrane, dispensed into sterile centrifuge tubes, labeled with the group, concentration and preparation time, and stored at 4°C for later use. The solution should be prepared and used immediately to avoid repeated freeze-thaw cycles that may lead to a decrease in activity.

[0104] 2. Preparation of LPS working solution: Accurately weigh an appropriate amount of LPS, dissolve it in sterile PBS buffer to prepare a stock solution with a concentration of 100 μg / mL, filter it through a 0.22 μm filter membrane for sterilization, aliquot it and store it at -20℃. Before use, dilute it with complete culture medium to the working concentration (1 μg / mL) and avoid repeated freeze-thaw cycles.

[0105] 3. Cell seeding and adherent culture: Dermal papilla cells in the logarithmic growth phase were digested with 0.25% trypsin, centrifuged (1000 r / min, 5 min), the supernatant was discarded, and the cells were resuspended in complete culture medium and the cell density was adjusted to 1 × 10⁶ cells / year. 4 Cells were placed in 96-well plates according to the grouping order, and 100 μL of cell suspension was added to each well. 100 μL of sterile PBS buffer was added to the edge wells to eliminate the edge effect. The plates were placed in a 37°C, 5% CO2 incubator and cultured statically for 24 h. When the cell adhesion and confluence rate reached 80%~90%, the morphology was uniform and there was no contamination, drug administration and modeling were performed.

[0106] 4. Grouped drug administration and inflammation modeling: ① Drug administration treatment: Discard the old culture medium in each well. Add 100 μL of complete culture medium + 10 μL of sterile PBS buffer to the blank control group, add 100 μL of complete culture medium + 10 μL of sterile PBS buffer to the model control group, and add 100 μL of complete culture medium + 10 μL of the corresponding compound working solution to the single compound group and the combination group, respectively; ② Incubation pretreatment: After drug administration, incubate in an incubator for 2 h to allow the compound to fully interact with the cells; ③ Inflammation modeling: Except for the normal control group, accurately add 1 μL of LPS working solution (final concentration 1 μg / mL) to each well of the other groups, gently pipette to mix, add 1 μL of sterile PBS buffer to the normal control group, and incubate in a 37℃, 5% CO2 constant temperature incubator until the optimal time point (e.g., 48 h).

[0107] 5. Collection of cell supernatant: After culture, remove the 96-well plate and centrifuge it using a high-speed refrigerated centrifuge (1500 r / min, 10 min, 4℃). Carefully aspirate the supernatant from each well (avoid aspirating cell pellets) and transfer it to a sterile centrifuge tube. Store at 4℃ for later use. Perform ELISA detection within 24 hours to avoid degradation of inflammatory factors.

[0108] 6. ELISA Detection (follow the kit instructions; for IL-6 detection, the procedure is the same for IL-8 and TNF-α): ① Coating: Dilute the IL-6 capture antibody according to the kit ratio, add 100 μL to each well, and incubate overnight at 4°C; ② Blocking: Discard the coating solution, wash 3 times with washing buffer for 3 min each time, add 200 μL of blocking buffer to each well, and incubate at 37°C for 1 h; ③ Sample Loading: Discard the blocking buffer, wash 3 times, add 100 μL of collected cell supernatant to each well (standards should be serially diluted according to the kit and added simultaneously), and incubate at 37°C for 1.5 h; ④ Add Detection Antibody: Discard the sample solution, wash 3 times, add 100 μL of diluted detection antibody to each well, and incubate at 37°C for 1 h; ⑤ Add Enzyme Conjugate: Discard the detection antibody solution, wash 3 times, add 100 μL of enzyme conjugate to each well, and incubate at 37°C for 30 min; ⑥ Color development: Discard the enzyme conjugate, wash 5 times, add 100 μL of color development solution to each well, and incubate at 37°C in the dark for 15 min; ⑦ Termination: Add 50 μL of stop solution to each well, mix gently, and measure the OD value of each well at 450 nm wavelength using a microplate reader within 10 min, and record the data.

[0109] 7. Data Correction and Calculation of Inflammatory Factor Content: ① Data Correction: Corrected OD value of each group = measured average OD value of the group - average OD value of blank wells (blank control of the kit); ② Standard Curve Plotting: Plot a standard curve with the concentration of IL-6 / TNF-α standard as the x-axis and the corresponding corrected OD value as the y-axis, and fit a regression equation (R²≥0.99 is considered valid); ③ Content Calculation: Substitute the corrected OD value of each experimental group into the regression equation to calculate the concentration (pg / mL) of IL-6 and TNF-α in the corresponding supernatant.

[0110] 8. Anti-inflammatory rate calculation: The anti-inflammatory rate of each group against IL-6 and TNF-α was calculated according to the formula "Anti-inflammatory rate (%) = (Inflammatory factor concentration in model control group - Inflammatory factor concentration in experimental group) / (Inflammatory factor concentration in model control group - Inflammatory factor concentration in normal control group) × 100%", and the average of the two was taken as the comprehensive anti-inflammatory rate of the group.

[0111] 9. Experimental Reproducibility and Quality Control: Each group was set up with 6 replicates, and 3 independent experiments were carried out in parallel. Normal control and model control were set up simultaneously in each experiment to ensure data reliability. During the experiment, the culture temperature, CO2 concentration and reagent incubation time were recorded as the basis for quality control. If the concentration of inflammatory factors in the model control group was more than 3 times that in the normal control group, it indicates that the inflammation model was successfully established. Otherwise, the LPS concentration needs to be adjusted and the experiment repeated.

[0112] 10. Experimental Conclusion: After the test is completed, dispose of the waste culture plates, cell pellets and reagents in accordance with biosafety regulations, organize the original experimental data, OD value record table, inflammatory factor concentration calculation table and anti-inflammatory rate statistics table, and archive them for subsequent analysis.

[0113] 11. Experimental Results (Anti-inflammatory Rate) A: IL-6 inhibition status: No inhibitory effect: Zinc pyrithione (5.6%) showed no significant difference from the model group; Moderate inhibition: supramolecular salicylic acid (14.1%), bisabolol (30.3%), gentiopicrin (34.9%); Strong inhibitory effects: quercetin (50.0%), tea saponin (55.9%), caffeine (59.7%), rosmarinic acid (65.5%); Strongest inhibition: Combination group (84.3%), significantly better than all single components (p<0.05) B: IL-8 inhibition status: Inactive: Zinc pyrithione (6.4%) showed no significant inhibitory effect; Moderate activity: supramolecular salicylic acid (17.2%), bisabolol (32.8%), gentiopicrin (41.4%). Highly active ingredients: quercetin (54.0%), tea saponin (60.3%), caffeine (66.5%), rosmarinic acid (72.8%). Strongest activity: Composition group (88.6%) C: Inhibition of TNF-α: Inactive: Zinc pyrithione (6.7%) showed no significant inhibitory effect; Moderate activity: supramolecular salicylic acid (19.8%), bisabolol (32.0%); High activity: gentiopicrin (46.7%), quercetin (53.9%), tea saponin (60.8%), caffeine (68.3%), rosmarinic acid (77.1%); Strongest activity: Composition group (90.0%).

[0114] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A composition, characterized in that, By weight, it includes 0.8-1.2 parts zinc pyrithione, 0.5-0.8 parts salicylic acid, 0.1-0.2 parts bisabolol, 0.2-0.4 parts gentian extract, 0.3-0.5 parts purslane extract, 0.5-1.0 parts camellia seed cake extract, 0.1-0.3 parts caffeine, and 0.3-0.5 parts rosemary extract.

2. The composition according to claim 1, characterized in that, Meet at least one of the following: (a) The composition comprises, by weight, 1.0 parts zinc pyrithione, 0.6 parts salicylic acid, 0.15 parts bisabolol, 0.3 parts gentian extract, 0.4 parts purslane extract, 0.75 parts camellia seed cake extract, 0.2 parts caffeine, and 0.4 parts rosemary extract; (b) The composition does not include selenium disulfide.

3. The composition according to claim 1 or 2, characterized in that, Meet at least one of the following: (a) The gentian extract includes gentiopicrin; (b) Purslane extract includes quercetin; (c) Camellia seed cake extract includes tea saponins; (d) Rosemary extract includes rosmarinic acid; (e) The salicylic acid is supramolecular salicylic acid, wherein the supramolecular salicylic acid contains 0.5-0.8 parts of salicylic acid.

4. The composition according to claim 1 or 2, characterized in that, Meet at least one of the following: (a) The salicylic acid is supramolecular salicylic acid, wherein the supramolecular salicylic acid contains 0.6 parts of salicylic acid; (b) The composition further comprises, by weight, 12.0-14.0 parts sodium lauryl ether sulfate, 4.0-5.0 parts cocamidopropyl betaine, and 2.0-3.0 parts cocamidopropylamine oxide.

5. A method for preparing the composition according to any one of claims 1-4, characterized in that, include: A first mixture was prepared by mixing water with glycerol, panthenol, and sodium gluconate. Sodium lauryl ether sulfate, cocamidopropyl betaine, and cocamidopropylamine oxide were added to the first mixture and mixed to prepare the second mixture. Zinc pyrithione was mixed with hydrogenated castor oil and propylene glycol to prepare a third mixture; Add stearamide-propyl dimethylamine and polyquaternium-7 to the first mixture, mix, and prepare the fourth mixture; Add the third mixture and supramolecular salicylic acid to the fourth mixture to obtain the fifth mixture; Add bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract to the fifth mixture to obtain the sixth mixture.

6. The method for preparing the composition according to claim 5, characterized in that, Meet at least one of the following: (a) Mix at 75±2℃ to prepare the first mixture; (b) Mix at 30 rpm to prepare the first mixture; (c) Mix for 15 min to prepare the first mixture; (d) Mix at 75±2℃ to prepare a second mixture; (e) Mix at 50 rpm to prepare a second mixture; (f) Mix for 20 min to prepare the second mixture; (g) Hydrogenated castor oil is PEG-40 hydrogenated castor oil; (h) Mix at 5000 rpm to prepare the third mixture; (i) Mix for 10 min to prepare the third mixture; (j) Stearamide-propyl dimethylamine and polyquaternium-7 were added to the first mixture at 70±2℃ to prepare the fourth mixture; (k) Mix at 5000 rpm to prepare a fourth mixture; (l) Mix for 15 min to prepare the fourth mixture; (m) Cool the fourth mixture to 60°C, add the third mixture and supramolecular salicylic acid to the fourth mixture to obtain the fifth mixture; (n) Cool the fifth mixture to 45°C, and add bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract to the fifth mixture to obtain the sixth mixture; (o) The preparation method of supramolecular salicylic acid includes: mixing salicylic acid with cyclodextrin; (p) In the preparation method of supramolecular salicylic acid, salicylic acid is mixed with β-cyclodextrin; (q) In the preparation method of supramolecular salicylic acid, salicylic acid and cyclodextrin are mixed in a mass ratio of 1:3; (r) In the preparation method of supramolecular salicylic acid, the mixture is mixed at 50°C; (s) In the preparation method of supramolecular salicylic acid, the mixture is mixed for 2 hours.

7. The method for preparing the composition according to claim 5 or 6, characterized in that, Meet at least one of the following: (a) The mass ratio of water to glycerol, panthenol, and sodium gluconate is (68–72):(1.8–2.2):(0.4–0.6):(0.2–0.4). (b) The mass ratio of the first mixture to sodium lauryl ether sulfate, cocamidopropyl betaine, and cocamidopropylamine oxide is (71.0–74.6):(2.3–2.7):(1.8–2.2):(0.8–1.2). (c) The mass ratio of zinc pyrithione to hydrogenated castor oil and propylene glycol is (0.9–1.1):(0.15–0.25):(0.9–1.1); (d) The mass ratio of the first mixture to stearamide propyl dimethylamine and polyquaternium-7 is (71.0–74.6):(1.3–1.7):(0.8–1.2). (e) The mass ratio of the fourth mixture to the third mixture and supramolecular salicylic acid is (73.8–76.8):(9.0–11.0):(11.0–13.0); (f) The mass ratio of the fifth mixture to bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract is (96.0–98.6):(0.13–0.17):(0.18–0.22):(0.18–0.22):(0.35–0.45):(0.18–0.22):(0.18–0.22). (g) Adjust the pH of the sixth mixture to 5.5–6.0; (h) Adjust the viscosity of the sixth mixture to 8000-12000 cps.

8. The method for preparing the composition according to claim 5 or 6, characterized in that, Meet at least one of the following: (a) The mass ratio of water to glycerol, panthenol, and sodium gluconate is 70:2:0.5:0.3; (b) The mass ratio of the first mixture to sodium lauryl ether sulfate, cocamidopropyl betaine, and cocamidopropylamine oxide is 72.8:2.5:2.0:1.0; (c) The mass ratio of zinc pyrithione to hydrogenated castor oil and propylene glycol is 1:0.2:1; (d) The mass ratio of the first mixture to stearamide propyl dimethylamine and polyquaternium-7 is 72.8:1.5:1.0; (e) The mass ratio of the fourth mixture to the third mixture and supramolecular salicylic acid is 75.3:10:12; (f) The mass ratio of the fifth mixture to bisabolol, gentian extract, purslane extract, camellia seed cake extract, caffeine, and rosemary extract was 97.3:0.15:0.2:0.2:0.4:0.2:0.2; (g) Adjust the pH of the sixth mixture prepared by the method of preparing the composition according to claim 5 to 5.5-6.0; (h) will The sixth mixture prepared by the method of preparing the composition according to claim 5 has a viscosity of 8000-12000 cps.

9. Use of the composition according to any one of claims 1-4 or the composition prepared by the method of preparation of the composition according to any one of claims 5-8 in the preparation of a product, wherein the product is selected from pharmaceuticals and daily chemical products.

10. The use according to claim 9, characterized in that, Meet at least one of the following: (a) The product is shampoo; (b) The product improves the area of ​​skin lesions, scalp stratum corneum moisture content, transepidermal water loss, sebum secretion and / or the quality of life index of dermatitis; (c) The product has high temperature stability, centrifugal stability, and freeze-thaw cycle stability; (d) The product is used for dandruff removal, anti-inflammation, hair strengthening and / or itch relief; (e) The product is a cosmetic; (f) The pH of the product is 5.5-6.0; (g) The product is a shampoo with a viscosity of 8000-12000 cps; (h) The product promotes the proliferation of dermal papilla cells; (i) The product inhibits Malassezia; (j) The product inhibits the expression of at least one of the inflammatory factors IL-6, IL-8 and TNF-α.

Images